IP Library Granted Patent US 12,631,643
Granted Patent B2
US 12,631,643 · App. 17/731,833 · Granted May 19, 2026

Tissue-derived extracellular vesicles and their use as diagnostics

Inventors: Jan Lötvall (Boston, MA); Su Chul Jang (Gyeongsangbuk-Do, KR); Rossella Crescitelli (Gothenburg, SE)
Assignee: Exocure Sweden AB
G01N33/57545C12N5/06G01N33/564G01N33/56977G01N33/5751G01N33/5759G01N33/57595G01N33/6842G01N33/6848
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,631,643
App. No.
17/731,833
Granted
May 19, 2026
Kind
B2
Abstract

The present disclosure relates to a method of isolating extracellular vesicles directly from human tissues. The invention further relates to a method of identifying disease and tissue specific membrane proteins on extracellular vesicles by membrane isolation and proteomic analysis. The invention further relates to methods of diagnosing diseases by capturing extracellular vesicles by the use of disease specific membrane proteins from body fluids, and detecting or analyzing molecular signatures (proteome, DNA, and RNA) on captured extracellular vesicles. Moreover, the present invention relates to kits, apparatus and software required for implementing aforementioned methods.

Claims (20)

1 . A method comprising the steps of:

(a) fragmenting a human tissue into a plurality of pieces;

(b) incubating the plurality of pieces with one or more enzymes, wherein the one or more enzymes are selected from a group of proteases including a matrix metalloproteinase, collagenases, and papain and nucleases including DNase, RNase, and Benzonase, wherein the incubating releases extracellular vesicles from the plurality of pieces, thereby generating a mixture of the extracellular vesicles, the plurality of pieces, and the one or more enzymes;

(c) isolating the extracellular vesicles from the mixture;

(d) treating the extracellular vesicles with an aqueous solution, wherein the aqueous solution has a pH in a range of 9 to 14 to generate membranes;

(e) isolating the membranes; and

(f) identifying proteins on the membranes by employing mass spectrometry to identify tissue specific membrane proteins.

2 . The method of claim 1 , wherein the human tissue comprises diseased tissue.

3 . The method of claim 2 , wherein the diseased tissue is a tumor.

4 . The method of claim 3 , wherein the tumor is a lung cancer, larynx cancer, stomach cancer, large intestine/rectal cancer, liver cancer, gallbladder cancer, pancreatic cancer, breast cancer, uterine cervical cancer, prostate cancer, or kidney cancer.

5 . The method of claim 3 , wherein the tumor is a melanoma, bone cancer, muscle cancer, adipose tissue sarcoma, or mesothelioma.

6 . The method of claim 3 , wherein the tumor is a neuroma, neuroblastoma, or medulloblastoma.

7 . The method of claim 1 , wherein the human tissue is liver, brain, kidney, heart, lung, skin, stomach, intestines, lymph nodes, bone marrow, peripheral or central nervous tissue, endocrine glands, adipose tissue or muscles.

8 . The method of claim 1 , wherein isolating the membranes at the step (e) comprises ultracentrifugation.

9 . The method of claim 2 , further comprising isolating extracellular vesicles from a diseased human tissue using a specific binder for a diseased tissue-specific membrane proteins identified in step (f) and characterizing at least one of:

i. their disease-specific proteome;

ii. their disease-related RNA cargo; and

iii. their disease-related DNA cargo.

10 . The method of claim 1 , wherein the enzymes comprise collagenase D and DNase I.

11 . The method of claim 1 , wherein isolating the extracellular vesicles at the step (c) comprises filtration of the mixture to generate a flow-through and centrifugation of the flow-through from the filtration to remove cells and tissue debris and provide a supernatant comprising the extracellular vesicles.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE NATURE OF CONVEYANCE ON THE COVERSHEET FOR THE ORIGINAL RECORDATION, NATURE OF CONVEYANCE SHOULD BE "ASSIGNMENT" AND NOT "CHANGE OF NAME". PREVIOUSLY RECORDED AT REEL: 64189 FRAME: 174. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 12, 2024
From: EXOCURE BIOSCIENCES, INC.
To: EXOCURE SWEDEN AB
Reel/Frame 069530/0601 →
CHANGE OF NAME Recorded Jul 7, 2023
From: EXOCURE BIOSCIENCES, INC.
To: EXOCURE SWEDEN AB
Reel/Frame 064189/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: LÖTVALL, JAN; JANG, SU C.; CRESCITELLI, ROSSELLA
To: EXOCURE BIOSCIENCES INC.
Reel/Frame 061516/0860 →
Priority Claims (1)
GB 1704646 · Mar 23, 2017 · national
Continuity (2)
Continuation 16494193
Related Publication 20220334120A1 · Oct 20, 2022
References Cited (49)
US 9149542B2 · Gho et al. · 2015 [cited by applicant]
US 9220763B2 · Gho et al. · 2015 [cited by applicant]
US 11333665B2 · Lotvall · 2022 [cited by examiner]
US 20080207723A1 · Kopreski · 2008 [cited by applicant]
US 20150086639A1 · Huang · 2015 [cited by applicant]
US 20150218254A1 · Sabbadini et al. · 2015 [cited by applicant]
US 20160061842A1 · Di Vizio · 2016 [cited by applicant]
US 20160120818A1 · Grandi et al. · 2016 [cited by applicant]
US 20170246288A1 · Li et al. · 2017 [cited by applicant]
US 20180036240A1 · Gho et al. · 2018 [cited by applicant]
US 20180296483A1 · Gho et al. · 2018 [cited by applicant]
US 20180318409A1 · Valiante et al. · 2018 [cited by applicant]
US 20200249234A1 · Lotvall et al. · 2020 [cited by applicant]
US 20220080035A1 · Park et al. · 2022 [cited by applicant]
EP 2617413A2 · 2013 [cited by applicant]
EP 3251659A1 · 2017 [cited by applicant]
EP 2450032B1 · 2018 [cited by applicant]
WO WO2009051427 · 2009 [cited by applicant]
WO WO2009130649 · 2009 [cited by applicant]
WO WO2009130649A2 · 2009 [cited by examiner]
WO WO2010010983 · 2010 [cited by applicant]
WO WO2010056337 · 2010 [cited by applicant]
WO WO2010070124 · 2010 [cited by applicant]
WO WO2013063439 · 2013 [cited by applicant]
WO WO2015085096 · 2015 [cited by applicant]
WO WO2016136372 · 2016 [cited by applicant]
WO WO2017161010 · 2017 [cited by applicant]
WO WO2017205810 · 2017 [cited by applicant]
WO WO2018171947 · 2018 [cited by applicant]
Romanov et al. (Cell Technologies in Biology and Medicine, No. 3, Nov. 2015, p. 148-154) (Year: 2015). [cited by examiner]
Vizio et al. (The American Journal of Pathology, vol. 181, No. 5, Nov. 2012, pp. 1573-1584). (Year: 2012). [cited by examiner]
Xavier et al. Molecular Neurodegeneration, published May 23, 2016, vol. 11, No. 41, pp. 1-13. (Year: 2016). [cited by examiner]
Corrales et al., (2015) “Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity”, Cell Reports, 11(7):1018-1030, XP055771217. [cited by applicant]
Morein et al. (1994) “Separation of inner and outer membrane vesicles from [cited by applicant]
Van Der Pol et al. (2015) “Outer membrane vesicles as platform vaccine technology”, Biotechnology Journal, 10(11):1689-1706, XP055465407. [cited by applicant]
Coumans et al., (2017) “Methodological guidelines to study extracellular Vesicles”, Circ. Res., 120(10):1632-1648. [cited by applicant]
Jeppesen et al., (2014) “Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors”, Proteo… [cited by applicant]
Karimi et al., (2018) “Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins”, Cell. Mol. Life Sci., 75(15):2873-2886. [cited by applicant]
Mariantonia et al., (2009) “High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. e5219”, PLOS One, 4(4):1-10. [cited by applicant]
Matsushita et al., (1989) “Effect of Extracellular pH on the Respiratory Chain and Energetics of Gluconobacter suboxydans”, Agricultural and Biological Chemistry,53(11):2895-2902. [cited by applicant]
Shin et al., (2015) “High-yield isolation of extracellular vesicles using aqueous two-phase system”, Scientific Reports, (5)1:1-11. [cited by applicant]
Tauro et al., (2012) “Two Distinct Populations of Exosomes Are Released from LIM1863 Colon Carcinoma Cell-derived Organoids”, Molecular & Cellular Proteomics, 12(3):587-598. [cited by applicant]
Yoshioka et al., (2014) “Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen”. Nature Communications, (5)3591:1-8. [cited by applicant]
U.S. Appl. No. 17/642,140, filed Mar. 10, 2022. [cited by applicant]
Filip et al., (1973) “Solubilization of the Cytoplasmic Membrane of [cited by applicant]
Zariri et al., (2016) “Meningococcal Outer Membrane Vesicle Composition-Dependent Activation of the Innate”, Immune Response, 84(10):3024-3033. [cited by applicant]
D'Atri et al., (2019) “Nano-Ghosts: mesenchymal stem cells derived nanoparticles as a novel approach for cartilage regeneration.” Journal of Extracellular Vesicles, vol. 8, 1 page. [cited by applicant]
Furman et al., (2013) “Reconstructed Stem Cell Nano ghosts: A Natural Tumor Targeting Platform.” Nano Letters, vol. 13, No. 7, pp. 3248-3255. [cited by applicant]
Go et al., (2018) “Extracellular Vesicle-Mimetic Ghost Nanovesicles for Delivering Anti-Inflammatory Drugs to Mitigate Gram-Negative Bacterial Outer Membrane Vesicle-Induced Systemic Inflammatory Response Syndrome.” Adv… [cited by applicant]